Physician profile
Daniel Fox
NPI 1215387626
$3,703.53
in general payments reported to CMS, 2019-2025
24 companies · $2,529 in 2025
The $2,529 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $131 · 2021: $16.76 · 2022: $181 · 2023: $153 · 2024: $223 · 2025: $2,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583 · Travel and Lodging: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.08 |
| Travel and Lodging | $1,321.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,875.36 | 2023-2025 | Evoque, Hemosphere |
| Abiomed | $282.76 | 2019-2025 | |
| Boston Scientific Corporation | $226.65 | 2019-2025 | Avvigo Guidance System |
| Abbott Laboratories | $218.60 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $178.07 | 2019-2025 | |
| Heartflow, INC. | $154.37 | 2025 | |
| Medtronic Vascular, INC. | $131.18 | 2020 | |
| Cardiovascular Systems INC. | $124.24 | 2019 | |
| Lantheus Medical Imaging, INC. | $73.26 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $53.84 | 2024-2025 | Camzyos |
| Kestra Medical Technology Services, INC. | $49.60 | 2025 | Assure Wcd |
| Novo Nordisk INC | $43.95 | 2025 | Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $37.66 | 2024-2025 | |
| Pfizer INC. | $32.89 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.68 | 2025 | Lifevest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.65 | 2024-2025 | Repatha, Repatha |
| Abbvie INC. | $27.46 | 2023 | |
| Cvrx, INC. | $24.21 | 2025 | Barostim Neo System |
| Medtronic, INC. | $22.18 | 2025 | Euphora |
| Cardiva Medical, INC. | $21.96 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Otsuka America Pharmaceutical, INC. | $20.61 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $15.50 | 2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $14.50 | 2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $14.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.